EPIX Nasdaq

ESSA Pharma Inc.

EPIX | $6.475 1.17% 1.16% 130K

(0.0% 1d) (-29.2% 1m) (136.2% 1y) (0.0% 2d) (0.0% 3d) (1.3% 7d) (19.51% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 286,454,000
http://www.essapharma.com
Sec Filling | Patents | 25 employees

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

cancer prostate cancer molecule drugs

add to watch list Paper trade email alert is off

Press-releases

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| -20.79% | O: 5.32% H: 0.0% C: -9.17%
pharma conference

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-06 (Crawled : 15:00) - biospace.com/
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| -36.06% | O: 2.4% H: 3.8% C: 2.83%
pharma conference life sciences

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Published: 2024-01-25 (Crawled : 20:00) - biospace.com/
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| -27.19% | O: 0.46% H: 3.06% C: -22.99%
epi-7386 pharma symposium asco

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
Published: 2023-12-12 (Crawled : 12:00) - prnewswire.com
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| 19.63% | O: -1.87% H: 5.71% C: 4.76%
pharma year update financial results

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
Published: 2023-11-21 (Crawled : 17:00) - biospace.com/
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| 18.52% | O: -1.11% H: 8.8% C: 8.8%
pharma conference

ESSA Pharma to Present at the Jefferies London Healthcare Conference
Published: 2023-11-08 (Crawled : 14:00) - biospace.com/
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| 25.24% | O: 1.17% H: 5.05% C: -1.55%
pharma conference

ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
Published: 2023-11-06 (Crawled : 23:00) - prnewswire.com
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| 22.84% | O: -0.19% H: 5.58% C: -1.73%
sales pharma offering agreement

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
Published: 2023-10-26 (Crawled : 22:00) - prnewswire.com
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| 59.4% | O: 4.36% H: 11.46% C: 5.49%
epi-7386 pharma cancer

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
Published: 2023-10-21 (Crawled : 16:20) - prnewswire.com
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| Email alert Add to watchlist
epi-7386 pharma congress medical

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Published: 2023-09-18 (Crawled : 11:00) - prnewswire.com
EPIX | $6.475 1.17% 1.16% 130K

Health Technology

| 141.51% | O: 1.51% H: 8.83% C: 3.35%
epi-7386 pharma cancer study

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950172-24-000180	4	2024-04-05	2024-04-05	Sell	S	694	11940
0000950172-24-000130	4	2024-03-28	2024-03-25	Buy	A	350000	350000
0000950172-24-000129	4	2024-03-28	2024-03-25	Buy	A	200000	200000